TY - JOUR
T1 - Selective effect of some somatostatin analogs on glucagon as opposed to insulin release in rats in vivo
AU - Lins, Per Eric
AU - Efendić, Suad
AU - Meyers, Chester A.
AU - Coy, David H.
AU - Schally, Andrew
AU - Luft, Rolf
N1 - Funding Information:
From the Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden, The Veterans Administration Hospital, and Tulane University School of Medicine, New Orleans, Louisiana. Received for publication October 16, 1979. Supported in part by NIH grant AM-18370, the Swedish Medical Research Council grant 19X-34-I2A. the Nordic Insulin Foundation (Gentofte. Denmark) and Svenska Liikaresiillskapets Eorskningsfond. Address reprint requests to Dr. Per-Eric Lins, Department of Endocrinology, Karolinska Hospital. Stockholm, Sweden. 0 I980 by Grune & Stratton, Inc. 0026&0495/80/2908-0005$01.00/0
PY - 1980
Y1 - 1980
N2 - Cyclic somatostatin, at a dose of 700 but not 70 ng/kg/min, inhibited arginine-induced insulin and glucagon release as well as glucose stimulated insulin release in rats in vivo. Three somatostatin (S-S) analogs (D-Cys14-S-S, D-Trp8-D-Cys14-S-S and Ala2-D-Trp8-D-Cys14-S-S), D-Trp8-D-Cys14-S-S and Ala2-D-Trp8-D-Cys14-S-S), at a dose of 70 ng/kg/min, suppressed arginine-induced glucagon but not insulin release. At the same dose, the first two of these analogs had no effect on glucose-induced insulin release, while the third one, Ala2-D-Trp8-D-Cys14-somatostatin, enhanced insulin release induced by glucose. A fourth analog, D-Trp8-somatostatin, was more potent than somatostatin with regard to arginine stimulated insulin and glucagon release, and equipotent with somatostatin with respect to glucose stimulated insulin release. These studies show, firstly, the inhibitory effect of somatostatin analogs on arginine induced insulin release may be different from that when glucose is used as a stimulant and, secondly, that Ala2-D-Trp8-D-Cys14-somatostatin inhibits arginine-induced glucagon release while enhancing insulin release on glucose stimulation.
AB - Cyclic somatostatin, at a dose of 700 but not 70 ng/kg/min, inhibited arginine-induced insulin and glucagon release as well as glucose stimulated insulin release in rats in vivo. Three somatostatin (S-S) analogs (D-Cys14-S-S, D-Trp8-D-Cys14-S-S and Ala2-D-Trp8-D-Cys14-S-S), D-Trp8-D-Cys14-S-S and Ala2-D-Trp8-D-Cys14-S-S), at a dose of 70 ng/kg/min, suppressed arginine-induced glucagon but not insulin release. At the same dose, the first two of these analogs had no effect on glucose-induced insulin release, while the third one, Ala2-D-Trp8-D-Cys14-somatostatin, enhanced insulin release induced by glucose. A fourth analog, D-Trp8-somatostatin, was more potent than somatostatin with regard to arginine stimulated insulin and glucagon release, and equipotent with somatostatin with respect to glucose stimulated insulin release. These studies show, firstly, the inhibitory effect of somatostatin analogs on arginine induced insulin release may be different from that when glucose is used as a stimulant and, secondly, that Ala2-D-Trp8-D-Cys14-somatostatin inhibits arginine-induced glucagon release while enhancing insulin release on glucose stimulation.
UR - http://www.scopus.com/inward/record.url?scp=0018939175&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018939175&partnerID=8YFLogxK
U2 - 10.1016/0026-0495(80)90194-8
DO - 10.1016/0026-0495(80)90194-8
M3 - Article
C2 - 6105610
AN - SCOPUS:0018939175
VL - 29
SP - 728
EP - 731
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
SN - 0026-0495
IS - 8
ER -